Retinoblastoma patients with high risk ocular pathological features: Who needs adjuvant therapy? Journal Article


Authors: Chantada, G. L.; Dunkel, I. J.; De Dávila, M. T. G.; Abramson, D. H.
Article Title: Retinoblastoma patients with high risk ocular pathological features: Who needs adjuvant therapy?
Abstract: Aims: To describe the outcome of patients with non-metastatic unilateral retinoblastoma with high risk histopathological features after primary enucleation, and to clarify the need and results of adjuvant therapy. Patients and methods: From 1980 to 2001 adjuvant therapy was recommended only to patients with scleral involvement, post-laminar optic nerve involvement (PLONI) with either a positive margin or associated choroidal involvement, or (before 1994) isotated PLONI. Results: 108 of 224 patients had at least one high risk feature (choroidal, scleral, anterior chamber, and/ or PLONI). Patients with isolated choroidal (n = 55) or anterior chamber (n = 2) invasion, and most with PLONI without other risk factors (n = 21 ) were not treated; three relapsed but are long term survivors after intensive therapy. Four with isolated PLONI received adjuvant chemotherapy and none relapsed. Three of 11 with PLONI and concomitant choroidal or scierai involvement who received adjuvant therapy relapsed, versus two of four not treated. Two of five with scleral disease relapsed. All 12 with cut end involvement received adjuvant treatment and none relapsed. In the total group, all four patients who relapsed after adjuvant therapy died. Conclusions: Relapsing patients can be rescued with intensive therapy. Those with isolated choroidal or PLONI have a good prognosis without adjuvant therapy. Patients with PLONI with a positive margin have a good prognosis if treated with combined therapy. Those with scleral involvement or PLONI with concomitant choroid disease may benefit from adjuvant therapy.
Keywords: adult; child; controlled study; treatment outcome; child, preschool; retrospective studies; major clinical study; adjuvant therapy; combined modality therapy; recurrence risk; antineoplastic agent; disease association; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; risk factors; retinoblastoma; retinal neoplasms; risk factor; risk assessment; cancer invasion; infant; recurrent disease; neoplasm invasiveness; eye enucleation; choroid; high risk population; optic nerve; sclera; choroid neoplasms; sclera disease; humans; human; male; female; priority journal; article; adjuvant disease; anterior eye chamber; anterior chamber; optic nerve neoplasms; scleral diseases
Journal Title: British Journal of Ophthalmology
Volume: 88
Issue: 8
ISSN: 0007-1161
Publisher: BMJ Publishing Group Ltd.  
Date Published: 2004-01-01
Start Page: 1069
End Page: 1073
Language: English
DOI: 10.1136/bjo.2003.037044
PROVIDER: scopus
PMCID: PMC1772257
PUBMED: 15258027
DOI/URL:
Notes: Br. J. Ophthalmol. -- Cited By (since 1996):51 -- Export Date: 16 June 2014 -- CODEN: BJOPA -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ira J Dunkel
    371 Dunkel